《世界卫生组织endTB方案治疗耐多药结核病指南》解读

doi:10.19983/j.issn.2096-8493.20250030

结核与肺部疾病杂志 ›› 2025, Vol. 6 ›› Issue (4): 361-364.doi: 10.19983/j.issn.2096-8493.20250030

《世界卫生组织endTB方案治疗耐多药结核病指南》解读

段鸿飞()

首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所结核科,北京 101149

收稿日期:2025-02-13 出版日期:2025-08-20 发布日期:2025-08-08
通信作者: 段鸿飞,Email: duanhongfei@hotmail.com
基金资助:
北京市高层次公共卫生人才建设项目(Disciplinary Leader-03-08)

Interpretation of the World Health Organization key updates for endTB regimens to treat multidrug-resistant tuberculosis

Duan Hongfei()

Department of Tuberculosis, Bejing Chest Hosptial, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

Received:2025-02-13 Online:2025-08-20 Published:2025-08-08
Contact: Duan Hongfei, Email:duanhongfei@hotmail.com
Supported by:
Beijing High-Level Public Health Talent Development Project(Disciplinary Leader-03-08)

摘要/Abstract

摘要：

耐多药结核病仍是人类健康的重大威胁。近期世界卫生组织根据 endTB 的研究推荐耐多药结核病治疗新方案。新方案包括贝达喹啉(Bdq)、德拉马尼(Del)、利奈唑胺(Lzd)、左氧氟沙星(Lfx)或莫西沙星(Mfx)、氯法齐明(Cfz)和吡嗪酰胺(Z)等药物。有效的方案包括Bdq-Lzd-Mfx-Z、Bdq-Cfz-Lzd-Lfx-Z和Bqd-Del-Lzd-Lfx-Z 等。新方案把短程方案适用人群扩大到病变广泛的耐多药结核病患者,而且适用于儿童、孕妇和HIV 感染者等特殊人群,无疑是耐多药结核病治疗的重要事件。作者针对 endTB的研究历程、适用人群和注意事项进行简要介绍。

关键词: 结核, 抗药性, 治疗应用, 总结性报告(主题)

Abstract:

Multidrug-resistant tuberculosis (MDR-TB) remains a major risk for human health. Recently, World Health Organization (WHO) has recommended new regimens for MDR-TB based on the endTB study. These regimens include drugs such as bedaquiline (Bdq), delamanid (Del), linezolid (Lzd), levofloxacin (Lfx) or moxifloxacin (Mfx), clofazimine (Cfz), and pyrazinamide (Z). Effective combinations include Bdq-Lzd-Mfx-Z, Bdq-Cfz-Lzd-Lfx-Z and Bqd-Del-Lzd-Lfx-Z. The new regimens expand the applicability of short-course regimens to MDR-TB patients with extensive lesions and are also suitable for special populations such as children, pregnant individuals, and people living with HIV. It is definitely an important event in the treatment of multidrug-resistant tuberculosis. The author briefly introduces research history, eligibility, and precautions of endTB study.

Key words: Tuberculosis, Drug resistance, Therapeutic uses, Consensus development conferences as topic

中图分类号:

段鸿飞. 《世界卫生组织endTB方案治疗耐多药结核病指南》解读[J]. 结核与肺部疾病杂志, 2025, 6(4): 361-364. doi: 10.19983/j.issn.2096-8493.20250030

Duan Hongfei. Interpretation of the World Health Organization key updates for endTB regimens to treat multidrug-resistant tuberculosis[J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 361-364. doi: 10.19983/j.issn.2096-8493.20250030

参考文献 13

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1): 15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	World Health organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[3]	World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication. Geneva: World Health Organization, 2024.
[4]	Guglielmetti L, Ardizzoni E, Atger M, et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials, 2021, 22(1):651. doi:10.1186/s13063-021-05491-3. pmid: 34563240
[5]	Guglielmetti L, Khan U, Velásquez GE, et al. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med, 2025, 392(5):468-482. doi:10.1056/NEJMoa2400327.
[6]	Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet, 2022, 400(10366):1858-1868. doi:10.1016/S0140-6736(22)02078-5. pmid: 36368336
[7]	Nyang’wa BT, Berry C, Kazounis E, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2022, 387(25):2331-2343. doi:10.1056/NEJMoa2117166.
[8]	World Health Organization. Management of drug-resistant tuberculosis in pregnant and peripartum people:a field guide. Boston: Sentinel Project for Pediatric Drug-Resistant Tuberculosis, 2022.
[9]	Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med, 2017, 377(11):1043-1054. doi:10.1056/NEJMoa1614915.
[10]	Xia H, Zheng Y, Liu D, et al. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013. Microbiol Spectr, 2021, 9(3):e0040921. doi:10.1128/Spectrum.00409-21.
[11]	Farhat M, Cox H, Ghanem M, et al. Drug-resistant tuberculosis: a persistent global health concern. Nat Rev Microbiol, 2024, 22(10):617-635. doi:10.1038/s41579-024-01025-1.
[12]	Goig GA, Loiseau C, Maghradze N, et al. Transmission as a Key Driver of Resistance to the New Tuberculosis Drugs. N Engl J Med, 2025, 392(1):97-99. doi:10.1056/NEJMc2404644.
[13]	Van Rie A, Walker T, de Jong B, et al. Balancing access to BPaLM regimens and risk of resistance. Lancet Infect Dis, 2022, 22(10):1411-1412. doi:10.1016/S1473-3099(22)00543-6. pmid: 36007529

[1]	杨超. 肠结核患者肛痿形成的危险因素分析及预防策略[J]. 结核与肺部疾病杂志, 2025, 6(S1): 5-7.
[2]	闭德武, 罗晓成, 何华伟, 罗晓璐. 618例耐多药结核病患者流行病学特征研究[J]. 结核与肺部疾病杂志, 2025, 6(S1): 47-51.
[3]	张京贝. 基于焦点解决模式的心理护理对妊娠女性肺结核患者的影响[J]. 结核与肺部疾病杂志, 2025, 6(S1): 67-69.
[4]	孙珍. 集束化消毒隔离管理在肺结核病房的应用及效果探讨[J]. 结核与肺部疾病杂志, 2025, 6(S1): 116-118.
[5]	中国防痨协会结核病控制专业分会, 中国防痨协会标准化专业分会, 中国防痨协会老年结核病防治专业分会. 结核分枝杆菌感染检测技术应用专家共识[J]. 结核与肺部疾病杂志, 2025, 6(4): 365-381.
[6]	中国防痨协会结核病基础专业分会. 中国结核分枝杆菌微量肉汤稀释法药物敏感性试验标准化专家共识[J]. 结核与肺部疾病杂志, 2025, 6(4): 382-392.
[7]	吴亦斐, 李清春, 贾庆军, 黄银燕, 白雪欣, 程庆林. 杭州郊县区非结核分枝杆菌肺病病原菌鉴定及其耐药性分析[J]. 结核与肺部疾病杂志, 2025, 6(4): 420-425.
[8]	魏云霞, 王鑫, 林红霞, 李义帅. 血清可溶性程序性死亡受体1与重症监护病房中肺结核患者病情及预后的关系研究[J]. 结核与肺部疾病杂志, 2025, 6(4): 426-431.
[9]	柳静, 赵月娟. 高海拔环境下肺结核与细菌性肺炎的超声影像学特征比较[J]. 结核与肺部疾病杂志, 2025, 6(4): 432-435.
[10]	刘彩芳, 宗华, 高云飞, 严瑾. 不同剂量艾司氯胺酮对胸腔镜手术肺结核患者围术期肺功能及术后肺部并发症的影响[J]. 结核与肺部疾病杂志, 2025, 6(4): 436-443.
[11]	魏黛珏, 孙建军, 陈彦, 王世军, 常亚梅, 魏念欢, 张鑫, 同重湘. 甘肃省2941株结核分枝杆菌临床分离株耐药情况分析[J]. 结核与肺部疾病杂志, 2025, 6(4): 444-448.
[12]	张文, 崔虹艳, 侯文俊. 2015—2024年北京市大兴区肺结核流行特征及季节性自回归移动平均模型建立[J]. 结核与肺部疾病杂志, 2025, 6(4): 449-455.
[13]	祁丹, 王昇, 刘敏, 高美琴, 石峰, 李兵, 白俊, 郝瑞霞, 王东. 2015—2024年内蒙古自治区鄂尔多斯市结核病定点医院肺结核患者病原学阳性检出情况分析[J]. 结核与肺部疾病杂志, 2025, 6(4): 456-463.
[14]	谢徐萍, 曾晓刚, 李福平, 孙楠楠, 余立梅, 蒋其龙, 唐文帅. 结核性心包炎预后影响因素及综合防治策略研究进展[J]. 结核与肺部疾病杂志, 2025, 6(4): 464-471.
[15]	邹晶晶, 蔡宾, 施吉霞, 杨丽, 张鲁敏. 慢性阻塞性肺疾病急性加重期患者营养管理的最佳证据总结[J]. 结核与肺部疾病杂志, 2025, 6(3): 261-268.

《世界卫生组织endTB方案治疗耐多药结核病指南》解读

Interpretation of the World Health Organization key updates for endTB regimens to treat multidrug-resistant tuberculosis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 13

相关文章 15

编辑推荐

Metrics

本文评价

友情链接